



NCIN Haematology Workshop 5th July 2013

Dr Ken Lloyd and Sue Forsey

SACT geographical coverage




5th June 2013

After first 12 months:

84% of trusts submitting data

101,000 patient records


185,000 regimens recorded



London detail

Increase in contributing trusts

Number of hospital trusts submitting chemotherapy data, by month of submission



SACT

- **S**ystemic **A**nti-**C**ancer **T**herapy Information Standard
- NHS Information Standard Board approval
- Implementation from April 2012- April 2014
- Covers all drug treatment for cancer in all settings

SACT field structure

- Demographics and provider
 - Clinical status
 - Programme and regimen
 - Cycle
 - Drug details
 - Outcome
- [Date of death added from ONS]

Data collection and analysis

- The Chemotherapy Intelligence Unit (CIU), is based at Oxford within the Cancer Registry
- Data are sent from trusts on a monthly basis and series of validation processes are applied
- A suite of routine analyses and reporting has been developed and the first year reports have just been issued

Data completeness

SACT Data Completeness report (April 2012 to April 2013)

	England						
Number of patients	% NHS Number	% Date of Birth	% Current gender	% Ethnicity	% Patient postcode		
107,206	100%	100%	97%	96%	100%		
Number of tumour records	% GP Practice Code	% GMC Code	% Consultant Specialty	% Primary diagnosis	% Morphology	% Stage of disease at start of programme	
118,074	76%	83%	83%	100%	37%	22%	
Number of regimens	% Programme number	% Regimen number	% Treatment intent	% Regimen name	% Height at start of regimen	% Weight at start of regimen	% Performance Status at start of regimen
198,409	49%	49%	64%	100%	42%	44%	23%
	% Comorbidity adjustment	% Date of decision to treat	% Start date of regimen	% Clinical trial	% Chemo radiation	% Number of cycles planned	
	12%	77%	100%	59%	42%	42%	
Number of cycles	% Cycle number	% Start date of cycle	% Weight at start of cycle	% Performance Status at start of cycle	% OPCS procurement code		
478,262	100%	85%	40%	20%	40%		
Number of drug records	% Drug name	% Actual dose per administration	% Administration route	% Administration date	% OPCS Delivery code	% Organisation code of drug provider	
1,018,168	100%	92%	82%	100%	48%	94%	

Analysis


April 2012-March 2013

Number of Patients by Diagnostic Group

All submitting trusts aggregated

Data received for April 2012 - March 2013. Patients aged 16 and over

Breast: 22,368 (22%)	Urology: 10,224 (10%)	Gynae: 7,446 (7%)	Head and Neck: 1,785 (2%)
Lower GI: 13,806 (14%)	Lymphoma: 8,933 (9%)	Myeloma: 3,915 (4%)	Brain/CNS: 1,557 (2%)
Lung: 11,993 (12%)	Upper GI: 8,240 (8%)	Leukaemia: 3,310 (3%)	Other: 6,651 (7%)




Top Regimens by Diagnostic Group

Leukaemia (All Leukaemia)

ICD10: C91-C95, C962, C964, C968

All submitting trusts aggregated

Data received for April 2012 - March 2013. Patients aged 16 and over




Top Regimens by Diagnostic Group

Leukaemia (ALL)

ICD10: C910, C915, C918

All submitting trusts aggregated

Data received for April 2012 - March 2013. Patients aged 16 and over




Top Regimens by Diagnostic Group

Leukaemia (AML)

ICD10: C920, C923-C926, C928, C93, C940, C942-C944, C962, C964, C968

All submitting trusts aggregated

Data received for April 2012 - March 2013. Patients aged 16 and over




Top Regimens by Diagnostic Group

Leukaemia (CLL)

ICD10: C911

All submitting trusts aggregated

Data received for April 2012 - March 2013. Patients aged 16 and over




Top Regimens by Diagnostic Group

Leukaemia (CML)

ICD10: C921

All submitting trusts aggregated

Data received for April 2012 - March 2013. Patients aged 16 and over




Top Regimens by Diagnostic Group

Lymphoma (All Lymphoma)

ICD10: C81-C86, C88, C913-C914, C916-C917, C919

All submitting trusts aggregated

Data received for April 2012 - March 2013. Patients aged 16 and over




Top Regimens by Diagnostic Group

Lymphoma (Hodgkin lymphoma)

ICD10: C81

All submitting trusts aggregated

Data received for April 2012 - March 2013. Patients aged 16 and over




Top Regimens by Diagnostic Group

Lymphoma (NHL aggressive)

ICD10: C824, C831, C833, C835, C837, C846-C847, C852

All submitting trusts aggregated

Data received for April 2012 - March 2013. Patients aged 16 and over




Top Regimens by Diagnostic Group

Lymphoma (NHL indolent)

ICD10: C82, C830, C880, C884, C913-C914, C916-C917, C919

All submitting trusts aggregated

Data received for April 2012 - March 2013. Patients aged 16 and over




Top Regimens by Diagnostic Group

Myeloma

ICD10: C90, D472, E85

All submitting trusts aggregated

Data received for April 2012 - March 2013. Patients aged 16 and over



Notes on benchmarking by trust

The Benchmarking report is intended to illustrate the variation in clinical practice between trusts in England for the major tumour groups.

Each trust can access a version of the charts with their trust identified.

The charts show the number of unique patients with a primary diagnosis recorded that matches the relevant diagnostic group.

The colour blocks represent the top regimens delivered nationally for that tumour group. The grey band includes other regimens administered by the trust, trials and regimens that cannot be mapped.


A minimum activity threshold has been applied for each tumour group. Trusts with lower levels of activity have been excluded from the analysis. Note that the scale varies between charts.

Regimen benchmarking

Lymphoma (NHL) ICD10: C82-C86, C88, C913-C914, C916-C917, C919

Data received for April 2012 - March 2013.

Group 1; Activity included where more than 50 patients aged 16 and over received treatment




Regimen benchmarking

Lymphoma (NHL) ICD10: C82-C86, C88, C913-C914, C916-C917, C919

Data received for April 2012 - March 2013.

Group 2; Activity included where more than 50 patients aged 16 and over received treatment




Regimen benchmarking

Lymphoma (NHL) ICD10: C82-C86, C88, C913-C914, C916-C917, C919

Data received for April 2012 - March 2013.

Group 3; Activity included where more than 50 patients aged 16 and over received treatment




Regimen benchmarking

Lymphoma (NHL) ICD10: C82-C86, C88, C913-C914, C916-C917, C919

Data received for April 2012 - March 2013.

Group 4; Activity included where more than 50 patients aged 16 and over received treatment




Regimen benchmarking

Lymphoma (NHL) ICD10: C82-C86, C88, C913-C914, C916-C917, C919

Data received for April 2012 - March 2013.

Group 5; Activity included where more than 50 patients aged 16 and over received treatment




Regimen benchmarking

Myeloma (All) ICD10: C90, D472, E85

Data received for April 2012 - March 2013.

Group 1; Activity included where more than 50 patients aged 16 and over received treatment




Regimen benchmarking

Myeloma (All) ICD10: C90, D472, E85


Data received for April 2012 - March 2013.

Group 2; Activity included where more than 50 patients aged 16 and over received treatment



Lymphoma Age analysis


Age profile of patients receiving chemotherapy Lymphoma (NHL)



Source: SACT, accessed 18th February 2013

† ICD10: C82, C824, C825, C830-C831, C833, C835, C837, C846-C847, C85, C852, C88, C880, C884, C913-C914, C916-C917, C919

Age profile of patients receiving chemotherapy Lymphoma (Hodgkin lymphoma)



Next steps

- Reviewing the SACT groupings for haematology
- Looking at ALL paediatrics + young adults
- New option for treatment intent – disease modification (D). This is defined as “an anticipated clinical improvement of at least a year’s duration”
- ?? – suggestions please

www.chemodataset.nhs.uk

ciu@sph.nhs.uk

Helpdesk 01865 334 770